Page of

Share this page

Share this page

Share this page

Share this page

Kite a Gilead Company - Yescarta

Prix Galien USA Award Laureates Book
https://www.theonlinebookcompany.com/OnlineBooks/Galien/Celebrations/Find?celebrationsSectionName=WinningProduct2018&name=kiteagileadcompanyyescarta

Leave a 'Tweet'

Add your tribute to this Research Team here in words, pictures and video clips.

Dear Colleague As a way of celebrating and sharing The Galien Awards, a page has been created within the $bookTitle$. Here we can all share our memories – through stories, thoughts, messages, photographs and videos. If you would like to visit the page and add your own message simply go to: $findPersonLink$. Thank you,
Previous Page Next

Winning Product 2018 by: Galien Foundation

Date added: 28 Dec 2018

Yescarta is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.
Next Previous